NMR Scanning on Patients

This study has been completed.

First Received: November 3, 1999 Last Updated: March 3, 2008 History of Changes

Sponsor:	National Institutes of Health Clinical Center (CC)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001194

Purpose

This protocol is designed to investigate the use of novel techniques in MRI that may not yet be commercially available. Specifically, the protocol enables patients to take advantage of new pulse sequence software, coil design or post processing capabilities not otherwise available. The informed consent explains MRI in lay terms, describes the use of contrast agents and lists contraindications to MRI.

Condition
Diagnostic Imaging

Study Type:	Observational
Official Title:	NMR Scanning on Patients

Resource links provided by NLM:

MedlinePlus related topics: Nuclear Scans

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	99999
Study Start Date:	April 1984
Estimated Study Completion Date:	February 2001

Detailed Description:

NMR imaging promises to provide useful and unique diagnostic information in a variety of diseases. In an attempt to evaluate its role, we plan to study a wide range of diseases during the initial year of imaging. Exposure to magnetic fields and radiofrequency energies of this magnitude have demonstrated no deleterious effects clinically or in the laboratory. The only restrictions will be those imposed by ferromagnetic objects within the patient which would increase the risk of placing them in a strong magnetic field.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Any patient undergoing MRI for research or clinical purposes who is participating in a currently active NIH protocol.

No patients with pacemakers, cochlear implants, implanted pumps, shrapnel, metal in the globe of the eye, cerebral aneurysm clips or other contraindication to MRI.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001194

Locations

United States, Maryland
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institutes of Health Clinical Center (CC)

More Information

Publications:

Choyke PL, Walther MM, Wagner JR, Rayford W, Lyne JC, Linehan WM. Renal cancer: preoperative evaluation with dual-phase three-dimensional MR angiography. Radiology. 1997 Dec;205(3):767-71.

Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: a review. Eur J Radiol. 1991 Jul-Aug;13(1):15-20. Review.

Study ID Numbers:	840058, 84-CC-0058
Study First Received:	November 3, 1999
Last Updated:	March 3, 2008
ClinicalTrials.gov Identifier:	NCT00001194 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Helium Cryogen
Magnetic Field
Multi-Institute
Nitrogen Cryogen
Radiofrequency

ClinicalTrials.gov processed this record on November 27, 2009